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Other Specific Nephropathies S59(r Z 0.273, p Z 0.044). Multivariate analysis confirmed that urinary
COL1A1 mRNA level is an independent predictor of serum creatinine
doubling (adjusted hazard ratio 1.023, p Z 0.016).
Conclusion: Urinary COL1A1 mRNA level is elevated in nephrotic patients
irrespective to the pathological diagnosis, and it correlates with proteinuria,
histological scarring, and inversely with renal function. Furthermore, urinary
COL1A1 mRNA level predicts renal function loss during follow up. Our results
suggest that urinary COL1A1 mRNA level may be used for risk stratification of
adult nephrotic syndrome.http://dx.doi.org/10.1016/j.hkjn.2015.09.0030006
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Background: Podocyte depletion is a characteristic feature of progressive
renal failure. We hypothesize that studying the podocyte mRNA level in uri-
nary sediment may provide diagnostic and prognostic information in adult
nephrotic syndrome.
Methods: We studied 25 patients with minimal change nephropathy (MCN),
25 with focal segmental glomerulosclerosis (FSGS), and 17 healthy controls.
The mRNA levels of nephrin, podocin and synaptopodin in urinary sediment
were quantified.
Results: There were significant differences in the urinary sediment nephrin
and podocin, but not synaptopodin, mRNA levels between diagnosis groups.
Post hoc analysis further shows that urinary nephrin mRNA levels of the MCN
group are lower than those in the control and FSGS groups, although the dif-
ference between MCN and FSGS Groups does not reach statistical signifi-
cance. The degree of proteinuria inversely correlates with urinary nephrin
mRNA levels in the MCN (r Z 0.526, p Z 0.007) as well as FSGS group
(r Z 0.521, p Z 0.008). For the FSGS group, the rate of renal function
decline significantly correlates with baseline urinary synaptopodin mRNA
levels (r Z 0.496, p Z 0.012).
Conclusion: Urinary nephrin and podocin mRNA levels are reduced in pa-
tients with MCN and probably FSGS, and the magnitude of reduction corre-
lates with the degree of proteinuria. Urinary synaptopodin mRNA levels
correlate with the subsequent rate of renal function decline in patients
with FSGS. Our result indicates that urine sediment podocyte mRNA levels
provide novel insights in the pathophysiology of nephrotic syndrome and
could be useful for risk stratification.http://dx.doi.org/10.1016/j.hkjn.2015.09.0040008
EGFR Inhibition Alleviates Hyperuricemic Nephropathy in Rats
Na Liu1, Li Wang1, Tao Yang3, Chongxiang Xiong2, Liuqing Xu1, Yingfeng Shi1,
Wenfang Bao1, Y. Eugene Chin4, Shi-Bin Cheng5, Haidong Yan1, Andong Qiu6,
Shougang Zhuang1,2
1Department of Nephrology, Shanghai East Hospital, Tongji University
School of Medicine, Shanghai, China
2Department of Medicine, Rhode Island Hospital and Brown University
School of Medicine, Providence, USA3Research Center for Translational Medicine Center, Shanghai East Hospital,
Tongji University School of Medicine, Shanghai, China
4Institute of Health Sciences, Chinese Academy of Sciences, Shanghai, China
5Department of Pediatrics, Women & Infants Hospital, Warren Alpert
Medical School of Brown University, Providence, USA
6School of Life Science and Technology, Advanced Institute of Translational
Medicine, Shanghai, China
Hyperuricemia is an independent risk factor for chronic kidney disease and
contributes to kidney fibrosis. In this study, we investigated the effect of
epidermal growth factor receptor (EGFR) inhibition on the development of
hyperuricemic nephropathy (HN) and the mechanisms involved. In a rat
model of HN induced by feeding a mixture of adenine and potassium
oxonate, increased EGFR phosphorylation and severe glomerular sclerosis
and renal interstitial fibrosis were evident, accompanied by renal dysfunc-
tion and increased urine microalbumin excretion. Administration of gefiti-
nib, a highly selective EGFR inhibitor, prevented renal dysfunction, reduced
urine microalbumin and inhibited activation of renal interstitial fibroblasts
and expression of extracellular proteins. Gefitinib treatment also inhibited
hyperuricemia-induced activation of the transforming growth factor-b1
(TGF-b1) and nuclear factor-kB (NF-kB) signaling pathways and expression
of multiple profibrogenic cytokines/chemokines in the kidney. Furthermore,
gefitinib treatment suppressed xanthine oxidase activity which mediates
uric acid production, and preserved expression of organic anion transporters
1 and 3, which promotes uric acid excretion in the kidney of hyperuricemic
rats. Thus, blocking EGFR can attenuate development of HN via suppression
of TGF-b1 signaling and inflammation, and promotion of the molecular
processes that reduce uric acid accumulation in the body.http://dx.doi.org/10.1016/j.hkjn.2015.09.0050015
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Objective: Glial cell line-derived neurotrophic factor (GDNF), a memberof
TGF-b superfamily, was testified to have protective effect on podocyte in
vitro. Helix B surface peptide (HBSP), derived from erythropoietin, displays
powerful tissue protection during kidney ischemia reperfusion (IR) injury
without erythropoietic side effects. The purpose of this study was to
explore the renoprotection effect of HBSP in puromycin aminonucleo-
side-induced nephrotic syndrome for the first time, and the change of
GDNF involved in.
Methods: Wistar rats were randomly divided into three groups, (1) Control
group (n Z 4); (2) PAN+vehicle group (n Z 6); (3) PAN+HBSP group
(n Z 8), which treated with HBSP (8 nmol/kg), 4 hours before the injection
of PAN (60 mg/kg) and every 24 hours after. Biochemical parameters, gene
expression and histology were assessed at 7 days.
Results: The levels of proteinuria significantly increased in rats with PAN-
induced nephrosis. Treatment with HBSP significantly prevented these dete-
riorations induced by PAN. Glomerular lesions, especially vacuolation of
podocytes, and the increase of desmin expression in PAN-treated rats
were significantly ameliorated by treatment with HBSP. The GDNF was
increased in in rats with PAN-induced nephrosis and increased further after
treated with HBSP. We also found activation of the RAS/ERK signaling
pathway in HBSP-treated rats.
Conclusion: HBSP could ameliorate proteinuria in PAN-induced nephrosis,
which might be due to the amelioration of podocyte injury. HBSP inhibited
the depletion of podocin. Increasing expression of GDNF and activation of
downstream RAS/ERK signaling pathway can be involved in the renoprotec-
tive effect of HBSP. GDNF might be involved in the renoprotective effect
of HBSP.
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Background: Aristolochic acid nephropathy (AAN) is a progressive chronic
kidney disease related to the use of Chinese herbal medicine and is charac-
terized by extensive tubulointerstitial fibrosis and inflammation with macro-
phage infiltration. However, treatment of AAN remains ineffective. Thus,
the present study aimed to develop a new therapeutic strategy for chronic
AAN by targeting macrophages with a selective inhibitor of tyrosine kinase
activity of macrophage colony-stimulating factor receptor (fms-I).
Methods: Chronic AAN was induced in C57BL/6 mice by intraperitoneal in-
jection of aristolochic acid at a dose of 5 mg/kg every other day for 4 weeks.
fms-I in an optimal dose of 10 mg/kg twice daily (i.p) was given at the begin-
ning of induction of AAN or at the established AAN on day 14. The therapeu-
tic effect of fms-I on chronic AAN was examined at day 28.
Results: Treatment with fms-I largely suppressed F4/80+ macrophage and
CD3+ T cell infiltration and upregulation of proinflammatory cytokines (MIF,
TNFa, MCP-1), resulting in protection against acute and chronic AAN by
inhibiting 24-hour proteinuria, elevated levels of serum creatinine, upregu-
lation of KIM-1, and progressive renal fibrosis including accumulation of a-
SMA+ myofibroblasts and collagen I. Moreover, administration of fms-I to
the established AAN at day 14 also halted the disease progression of chronic
AAN at day 28. Further studies revealed that the therapeutic effect of fms-I
on chronic AAN was associated with blockade of both NF-kB and TGF-b/Smad
pathways.Conclusion: Macrophages play a pathogenic role in the development of
chronic AAN. Targeting macrophages with fms-I has therapeutic potential
for chronic AAN.http://dx.doi.org/10.1016/j.hkjn.2015.09.0070059
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Objective: Autosomal dominant polycystic kidney disease (ADPKD), an
inherited disease characterized by massive enlargement of fluid-filled cysts
in the kidney with an incidence rate of 1:1000e1:400, is a common cause of
renal failure. There is no effective therapy for ADPKD. Repulsive guidance
molecular b (RGMb), a co-receptor for bone morphogenetic protein
signaling and also a ligand for neogenin, is expressed at the epithelial cells
in kidney. RGMb has been reported to induce apoptosis in renal tubular
cells. The aim of this study was to determine if RGMb played a role in
ADPKD development.
Methods: MDCK cyst model, embryonic kidney cyst model and Pkd1flox/+;
Ksp-Cre PKD mouse model were used to assess the effect of RGMb in ADPKD.
Results: The experimental results showed that RGMb overexpression inhibited
MDCK cyst formation in 3D collagen matrix. Compared with control MDCK cells
whose cysts contained a single lumen with forskolin stimulation, RGMb-MDCK
cells sprawled into the colonies without cystic structure. A few of identifiable
cysts containedmultiple smaller lumensand thickerwalls. H&E staining showed
that RGMbnull kidneyshad interstitial hyperplasia anddecreased tubular struc-
tures, especially in theboundary area of renal cortex andmedulla. DBA staining
revealed less branched uretic bud in E13.5 RGMb null mouse embryonic kidney,
which suggested that deficiency of RGMbwould retard uretic budbranchingand
negatively modulate collecting duct development. Western blot analysis
exhibited increased phosphorylation of Smad1/5/8 in RGMb-MDCK cells, indi-
cating BMP-Smad1/5/8 pathway was important in ADPKD development.
Conclusion: Our data suggest that RGMb plays an important role in kidney
development and inhibits ADPKD by regulating BMP-Smad1/5/8 pathway.http://dx.doi.org/10.1016/j.hkjn.2015.09.0080061
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Objective: We demonstrated that the outcome of treating AL amyloidosis
with bortezomib-dexamethasone (BD) induction followed by autologous
hematopoietic stem cell transplantation (ASCT) was superior to the
outcome of the ASCT treatment alone previously. To further improve the
hematologic response rate, we conducted a prospective trial of bortezo-
mib before, in and after ASCT in patients with newly diagnosed AL
amyloidosis.
Methods: Newly diagnosed AL amyloidosis patients who met the criteria of
ASCT could be included. Treatment schedule consisted of two cycles of BD
induction therapy (bortezomib 1.3 mg/m2 and dexamethasone 40 mg/d on
days 1, 4, 8 and 11 followed by 10 days of rest), ASCT treatment (the condi-
tioning regimen consisted of melphalan and bortezomib, the dose of borte-
zomib was 1 mg/m2 on days 6, 3, +1, +4), and four additional 21-day
cycles of bortezomib treatment (with a dose of 1.6 mg/m2 on days 1 and 8
of the cycle) will be conducted as consolidation therapy after ASCT. Hema-
tologic response, tolerability and survival were observed.
